Aditxt Inc (ADTX) Stock Price, Quote & News

Company Profile

Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 870 1200

Website: www.aditxt.com

Address:

2569 Wyandotte Street, Suite 101, Mountain View, United States

Derek_Davis Sep. 13 at 5:42 PM

$ADTX You should expect the Form 8-K containing the official voting results to be filed within four business days after the meeting concludes. [1] Because the meeting is scheduled for Monday, September 14, 2026, the strict regulatory deadline set by the U.S. Securities and Exchange Commission (SEC) under Item 5.07 (Submission of Matters to a Vote of Security Holders) is Friday, September 18, 2026. [1] Typical Filing Timelines The Rapid Scenario (1–2 Days): For highly anticipated or time-sensitive corporate restructurings, companies frequently issue a press release or file a preliminary Form 8-K within 24 to 48 hours to keep the market informed and sustain positive trading momentum.

0 · Reply

Jeffartist Sep. 13 at 5:20 PM

$BCDS $ADTX

0 · Reply

Steve_Lattimer Sep. 13 at 4:55 PM

$ADTX Freeing up money for tomorrow. I’m hoping to load heavily anything under .0070.

0 · Reply

Comando1 Sep. 13 at 8:50 AM

$ADTX ⏳️💰

0 · Reply

mkinvestinggroup Sep. 13 at 6:27 AM

$ADTX BDPT join the mars mission soon or be left behind 😄

1 · Reply

kl7777 Sep. 13 at 1:36 AM

$ADTX Bulls, more support would help.

1 · Reply

waywardmx5 Sep. 13 at 1:12 AM

$ADTX Every single day in here on Stocktwits begging the company for updates and then liking his own posts. 😂

1 · Reply

kl7777 Sep. 13 at 12:25 AM

$ADTX Others' comments? Well, as you all know, be ready Bulls, Monday. Need to have a big green day. Hopefully. CEO Busch, mgmt of Adtx, Ignite, Copley, Today is Sept. 12th. Again, already three months after signing the definitive agreement. Be on time. Release news/updates shortly.

0 · Reply

Derek_Davis Sep. 12 at 9:41 PM

$ADTX this is a bot. Don't waste your time responding to it

1 · Reply

Jordygirl99 Sep. 12 at 8:02 PM

$ADTX what do you guys think makes Adtx special and diffent than other penny stocks who were throught to explode but never did?

0 · Reply

Why Is Penny Stock Aditxt (ADTX) Up Today?

2026-06-09T11:50:09.000Z - 3 months ago

Aditxt signs agreement valuing Ignite Proteomics at $150M

Jun 9, 2026, 7:45 AM EDT - 3 months ago

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Jun 8, 2026, 8:15 AM EDT - 3 months ago

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

2026-06-01T15:05:46.000Z - 3 months ago

Aditxt appoints Busch as interim CEO

Jun 1, 2026, 8:15 AM EDT - 3 months ago

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

2026-05-14T16:21:02.000Z - 4 months ago

Aditxt announces 1-for-27 reverse stock split

May 14, 2026, 8:15 AM EDT - 4 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

2026-04-20T12:30:43.000Z - 4 months ago

Aditxt announces publication featuring Ignite Proteomics subsidiary

Apr 20, 2026, 8:15 AM EDT - 4 months ago

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

2026-04-13T10:11:46.000Z - 5 months ago

Aditxt files to sell 148.28M shares of common stock for holders

Mar 19, 2026, 8:15 AM EDT - 5 months ago

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

2026-03-13T12:55:13.000Z - 6 months ago

Aditxt acquires Ignite Proteomics in $36M transaction

Mar 13, 2026, 8:15 AM EDT - 6 months ago

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

2026-03-05T14:03:50.000Z - 6 months ago

Aditxt to effect 1-for-8 reverse split of common stock

Mar 5, 2026, 8:30 AM EST - 6 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

2025-12-02T16:19:00.000Z - 9 months ago

3 Penny Stocks to Watch Now, 12/2/25

BEAM KTTA

Nov 18, 2025, 8:00 AM EST - 9 months ago

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

2025-10-27T13:00:25.000Z - 10 months ago

Aditxt begins enrollment in Mitomic Endometriosis Test study

Oct 27, 2025, 8:30 AM EDT - 10 months ago

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Oct 20, 2025, 4:19 PM EDT - 10 months ago

Evofem Announces Voting Results from Special Meeting of Stockholders

Sep 11, 2025, 9:18 AM EDT - 1 year ago

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Sep 9, 2025, 9:28 AM EDT - 1 year ago

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Aug 25, 2025, 9:15 AM EDT - 1 year ago

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Aug 21, 2025, 8:56 AM EDT - 1 year ago

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Aug 19, 2025, 9:39 AM EDT - 1 year ago

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Aug 14, 2025, 8:46 AM EDT - 1 year ago

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aug 11, 2025, 8:30 AM EDT - 1 year ago

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Aug 5, 2025, 8:46 AM EDT - 1 year ago

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Jul 29, 2025, 9:00 AM EDT - 1 year ago

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Jul 24, 2025, 8:15 AM EDT - 1 year ago

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Jul 22, 2025, 8:15 AM EDT - 1 year ago

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Jul 15, 2025, 9:12 AM EDT - 1 year ago

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Jul 7, 2025, 8:15 AM EDT - 1 year ago

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Jun 26, 2025, 8:15 AM EDT - 1 year ago

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

2025-06-20T21:15:06.000Z - 1 year ago

Aditxt files to sell up to 50M shares of common stock for holders

Jun 11, 2025, 8:14 AM EDT - 1 year ago

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

2025-06-09T12:20:54.000Z - 1 year ago

Aditxt appoints Evofem CEO Saundra Pelletier to board

Jun 9, 2025, 8:15 AM EDT - 1 year ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Jun 5, 2025, 8:15 AM EDT - 1 year ago

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

2025-05-19T12:11:08.000Z - 1 year ago

Aditxt announces termination of arrangement agreement with Appili Therapeutics

May 19, 2025, 8:00 AM EDT - 1 year ago

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

May 2, 2025, 9:00 AM EDT - 1 year ago

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Apr 17, 2025, 8:15 AM EDT - 1 year ago

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Apr 16, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Apr 14, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Apr 11, 2025, 8:15 AM EDT - 1 year ago

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Apr 9, 2025, 8:15 AM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Apr 2, 2025, 8:15 AM EDT - 1 year ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Mar 28, 2025, 8:15 AM EDT - 1 year ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Mar 24, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Mar 17, 2025, 8:15 AM EDT - 1 year ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Mar 12, 2025, 4:15 PM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Mar 6, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Feb 21, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Feb 13, 2025, 8:15 AM EST - 1 year ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Jan 13, 2025, 8:15 AM EST - 1 year ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Dec 12, 2024, 8:15 AM EST - 1 year ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Nov 14, 2024, 4:36 PM EST - 1 year ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Derek_Davis Sep. 13 at 5:42 PM

0 · Reply

Jeffartist Sep. 13 at 5:20 PM

$BCDS $ADTX

0 · Reply

Steve_Lattimer Sep. 13 at 4:55 PM

$ADTX Freeing up money for tomorrow. I’m hoping to load heavily anything under .0070.

0 · Reply

Comando1 Sep. 13 at 8:50 AM

$ADTX ⏳️💰

0 · Reply

mkinvestinggroup Sep. 13 at 6:27 AM

$ADTX BDPT join the mars mission soon or be left behind 😄

1 · Reply

kl7777 Sep. 13 at 1:36 AM

$ADTX Bulls, more support would help.

1 · Reply

waywardmx5 Sep. 13 at 1:12 AM

$ADTX Every single day in here on Stocktwits begging the company for updates and then liking his own posts. 😂

1 · Reply

kl7777 Sep. 13 at 12:25 AM

0 · Reply

Derek_Davis Sep. 12 at 9:41 PM

$ADTX this is a bot. Don't waste your time responding to it

1 · Reply

Jordygirl99 Sep. 12 at 8:02 PM

$ADTX what do you guys think makes Adtx special and diffent than other penny stocks who were throught to explode but never did?

0 · Reply

2damoon84 Sep. 12 at 5:30 PM

$ADTX all my research (which let’s be honest, is just an AI search) says Monday’s meeting is still on. Anyone here anything else/different? If not, this thing better fucking soar next week.

0 · Reply

2damoon84 Sep. 12 at 3:08 PM

$ADTX

0 · Reply

Comando1 Sep. 12 at 12:13 PM

$ADTX ⏳️🤫

0 · Reply

Romeogattone Sep. 12 at 12:03 PM

$ADTX

0 · Reply

mkinvestinggroup Sep. 12 at 9:46 AM

$ADTX BDPT will pump to ADTX levels soon (now 0,0016 soon 0,006+)thats 300-400% in making holding both not trolling just sayin 😃 if BDPT had more folks in the comunity like here this baby can fly 0,01-0,02+ so who is here to make 10x? If you disagre I expect you explain why disagree. Have a nice weekend all

1 · Reply

luckydd Sep. 12 at 6:19 AM

$ADTX

0 · Reply

kl7777 Sep. 12 at 4:58 AM

$ADTX Very quiet here since 5pm. More comments could be helpful. Well, I do understand people are waiting for news. And, I'm not a bot BTW. To point something out, volume was 12.7 million today suddenly vs. 6.7 million the day before. Must be more selling and buying. Whether you agree, more volumes today 'cause a bullish inducement was happening?It's a bit hard to explain myself Well, "Trapping retail traders to panic sell and 'smart money' gather liquidity before reversal for higher high w/ surging buying volume?" Hopefully, this is the case for next week, Bulls.

0 · Reply

sullivan1 Sep. 11 at 10:51 PM

$BCDS looks good. But, $NMHI CEO owns 15% upto 80M shares. This could go into pennies in Oct, imo $ADTX $AMFN

2 · Reply

chaser84 Sep. 11 at 10:44 PM

$ADTX

0 · Reply

kl7777 Sep. 11 at 10:36 PM

$ADTX Some people may already know, numbers are out. Today, Short volume ratio: 47.3%, -Short volume: 6 million, total: 12.7 million -Yesterday: 57.2% As someone mentuoned, there must have been stop losses happening today and institutional buyers taking those cheap shares, possibly. Well, could have finished stronger after all, but I think people still added dips for support. CEO Busch, mgmt of Adtx, Ignite, Release news/updates shortly after all these times.

0 · Reply

Derek_Davis Sep. 11 at 10:22 PM

$ADTX yup, all week manipulation to push it down before big news drops. Accumulation barely even dropped. OTC trash mind games. That'll be over soon 🚀. RSI is primed and ready for another run.

0 · Reply

trt102967 Sep. 11 at 9:40 PM

$ADTX We will skull f@ck every short very very soon…encourage them to go balls deep…I want all their money

1 · Reply

Market Cap	8,000.00
Revenue (ttm)	3,195.00
Net Income (ttm)	-41.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	362,990,313
Avg Vol	302,860,438
Day's Range	N/A - N/A
Shares Out	816,000.00
Stochastic %K	0%
Beta	0.84
Analysts	Strong Buy
Price Target	$61.00